STE
STERIS plc$212.73
+0.51%Live · FMPMay 29, 2026
Market cap
$20.88B
52w range
195.14 – 269.44
P / E
—
EPS
—
Volume
484.76K
Revenue · FY
$5.46B
+6.24% YoY
Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$335.58
+57.75% vs spot
Strong Buy
Spot price
$212.73
Mkt cap $20.88B
subtle cardAnalyst PT consensus
$256.67
+20.66% vs spot
subtle cardMethods covered
18 / 19
15 in blend
subtle cardFootball field
STE · fair-value range by method
Method comparison
STE · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $709.16 | $443.10 – $1,317.13 | +233.36% | 22.3% | WACC 7.3%, g₀=25.0%, gₗ=4.6% | high |
| DCF · FCFE | dcf | $425.02 | $299.40 – $642.92 | +99.79% | 16.8% | kₑ 8.7%, g₀=25.0%, gₗ=4.6% | high |
| DDM · Gordon | ddm | $56.47 | $45.43 – $74.58 | -73.46% | — | D₁ 2.22, kₑ 8.7%, gₗ 4.6% | med |
| DDM · H-model | ddm | $111.54 | $83.23 – $158.01 | -47.57% | — | D₀ 2.22, g₀=25.0%, gₗ=4.6%, H 5y | med |
| DDM · multi-stage | ddm | $87.65 | $74.50 – $100.80 | -58.80% | 5.6% | 5y schedule 25.0% → 4.6%, kₑ 8.7% | high |
| Residual income | income | $67.74 | $59.62 – $75.87 | -68.15% | 11.2% | BV 66.88, ROE 9.3% → kₑ | high |
| EVA / MVA | income | $431.69 | $379.89 – $483.49 | +102.93% | 7.8% | IC 8.6B, WACC 7.3% | high |
| P/E · sector | multiple | $136.40 | $120.03 – $152.77 | -35.88% | 13.4% | EPS 6.20 × peer P/E 22.0 | med |
| P/S · sector | multiple | $220.77 | $187.65 – $253.89 | +3.78% | 3.4% | Rev/sh 55.19 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $185.50 | $163.24 – $207.76 | -12.80% | 11.2% | EBITDA × peer 15.0× − ND 2.0B | high |
| EV / EBIT | multiple | $137.17 | $116.60 – $157.75 | -35.52% | 2.2% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $167.12 | $142.06 – $192.19 | -21.44% | 2.2% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $248.00 | $210.80 – $285.20 | +16.58% | 1.1% | PEG=1, fwd EPS g 79.8% | med |
| Earnings power | intrinsic | $70.59 | $62.12 – $79.06 | -66.82% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $296.65 | $252.16 – $341.15 | +39.45% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $155.00 | $131.75 – $178.25 | -27.14% | 0.6% | PE = g (25.0) | low |
| Book NAV | asset | $66.88 | $63.54 – $70.23 | -68.56% | 1.1% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $36.63 | $31.13 – $42.12 | -82.78% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -1.6% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (0.95)β | × 0.95 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 8.71% |
| Pre-tax cost of debtkd | 3.92% |
| Effective tax ratet | 24.3% |
| After-tax cost of debt | 2.96% |
| Equity weight$6.6B | 75.0% |
| Debt weight$2.2B | 25.0% |
| WACC | 7.28% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 16.55% |
| Analyst forward EPS growthFMP | 79.82% |
| Historical 5y revenue CAGRFY | 15.13% |
| Historical 5y EPS CAGRFY | 7.57% |
| Sustainable g (ROE × retention)Δ | 5.97% |
| Blended near-term growth (g₀) | 25.00% |
| Terminal growth (gₗ) | 4.60% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2022-03-30)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $256.67
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.